These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 17527075)

  • 21. Molecular evidence that invasive adenocarcinoma can mimic prostatic intraepithelial neoplasia (PIN) and intraductal carcinoma through retrograde glandular colonization.
    Haffner MC; Weier C; Xu MM; Vaghasia A; Gürel B; Gümüşkaya B; Esopi DM; Fedor H; Tan HL; Kulac I; Hicks J; Isaacs WB; Lotan TL; Nelson WG; Yegnasubramanian S; De Marzo AM
    J Pathol; 2016 Jan; 238(1):31-41. PubMed ID: 26331372
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Detection of TMPRSS2-ERG fusion transcripts and prostate cancer antigen 3 in urinary sediments may improve diagnosis of prostate cancer.
    Hessels D; Smit FP; Verhaegh GW; Witjes JA; Cornel EB; Schalken JA
    Clin Cancer Res; 2007 Sep; 13(17):5103-8. PubMed ID: 17785564
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Single focus prostate cancer: pathological features and ERG fusion status.
    Falzarano SM; Zhou M; Hernandez AV; Klein EA; Rubin MA; Magi-Galluzzi C
    J Urol; 2011 Feb; 185(2):489-94. PubMed ID: 21167530
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Expression of the androgen-regulated fusion gene TMPRSS2-ERG does not predict response to endocrine treatment in hormone-naïve, node-positive prostate cancer.
    Boormans JL; Hermans KG; Made AC; van Leenders GJ; Wildhagen MF; Collette L; Schröder FH; Trapman J; Verhagen PC
    Eur Urol; 2010 May; 57(5):830-5. PubMed ID: 19716227
    [TBL] [Abstract][Full Text] [Related]  

  • 25. TMPRSS2:ERG fusion identifies a subgroup of prostate cancers with a favorable prognosis.
    Saramäki OR; Harjula AE; Martikainen PM; Vessella RL; Tammela TL; Visakorpi T
    Clin Cancer Res; 2008 Jun; 14(11):3395-400. PubMed ID: 18519769
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Characterization of TMPRSS2:ETV5 and SLC45A3:ETV5 gene fusions in prostate cancer.
    Helgeson BE; Tomlins SA; Shah N; Laxman B; Cao Q; Prensner JR; Cao X; Singla N; Montie JE; Varambally S; Mehra R; Chinnaiyan AM
    Cancer Res; 2008 Jan; 68(1):73-80. PubMed ID: 18172298
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer.
    Tomlins SA; Laxman B; Dhanasekaran SM; Helgeson BE; Cao X; Morris DS; Menon A; Jing X; Cao Q; Han B; Yu J; Wang L; Montie JE; Rubin MA; Pienta KJ; Roulston D; Shah RB; Varambally S; Mehra R; Chinnaiyan AM
    Nature; 2007 Aug; 448(7153):595-9. PubMed ID: 17671502
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The discovery of common recurrent transmembrane protease serine 2 (TMPRSS2)-erythroblastosis virus E26 transforming sequence (ETS) gene fusions in prostate cancer: significance and clinical implications.
    Shah RB; Chinnaiyan AM
    Adv Anat Pathol; 2009 May; 16(3):145-53. PubMed ID: 19395877
    [TBL] [Abstract][Full Text] [Related]  

  • 29. TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer.
    Tomlins SA; Mehra R; Rhodes DR; Smith LR; Roulston D; Helgeson BE; Cao X; Wei JT; Rubin MA; Shah RB; Chinnaiyan AM
    Cancer Res; 2006 Apr; 66(7):3396-400. PubMed ID: 16585160
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identification of novel TMPRSS2:ERG mechanisms in prostate cancer metastasis: involvement of MMP9 and PLXNA2.
    Tian TV; Tomavo N; Huot L; Flourens A; Bonnelye E; Flajollet S; Hot D; Leroy X; de Launoit Y; Duterque-Coquillaud M
    Oncogene; 2014 Apr; 33(17):2204-14. PubMed ID: 23708657
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Atypical adenomatous hyperplasia of prostate lacks TMPRSS2-ERG gene fusion.
    Cheng L; Davidson DD; Maclennan GT; Lopez-Beltran A; Montironi R; Wang M; Tan PH; Baldridge LA; Zhang S
    Am J Surg Pathol; 2013 Oct; 37(10):1550-4. PubMed ID: 23887154
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mapping of TMPRSS2-ERG fusions in the context of multi-focal prostate cancer.
    Furusato B; Gao CL; Ravindranath L; Chen Y; Cullen J; McLeod DG; Dobi A; Srivastava S; Petrovics G; Sesterhenn IA
    Mod Pathol; 2008 Feb; 21(2):67-75. PubMed ID: 18065961
    [TBL] [Abstract][Full Text] [Related]  

  • 33. TMPRSS2-ERG fusion is frequently observed in Gleason pattern 3 prostate cancer in a Canadian cohort.
    Darnel AD; Lafargue CJ; Vollmer RT; Corcos J; Bismar TA
    Cancer Biol Ther; 2009 Jan; 8(2):125-30. PubMed ID: 19029822
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of TMPRSS2-ERG mechanisms in prostate cancer invasiveness: Involvement of MMP-9 and plexin B1.
    Liu B; Gu X; Huang T; Luan Y; Ding X
    Oncol Rep; 2017 Jan; 37(1):201-208. PubMed ID: 28004109
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Relationship between TMPRSS2: ERG and the pathological grade of prostate cancer].
    Yi FX; Li H; Wei Q; Li X; Zeng H
    Zhonghua Nan Ke Xue; 2015 Oct; 21(10):887-91. PubMed ID: 26665675
    [TBL] [Abstract][Full Text] [Related]  

  • 36. TMPRSS2-ERG gene fusion prevalence and class are significantly different in prostate cancer of Caucasian, African-American and Japanese patients.
    Magi-Galluzzi C; Tsusuki T; Elson P; Simmerman K; LaFargue C; Esgueva R; Klein E; Rubin MA; Zhou M
    Prostate; 2011 Apr; 71(5):489-97. PubMed ID: 20878952
    [TBL] [Abstract][Full Text] [Related]  

  • 37. p53 Alteration and chromosomal instability in prostatic high-grade intraepithelial neoplasia and concurrent carcinoma: analysis by immunohistochemistry, interphase in situ hybridization, and sequencing of laser-captured microdissected specimens.
    Al-Maghrabi J; Vorobyova L; Chapman W; Jewett M; Zielenska M; Squire JA
    Mod Pathol; 2001 Dec; 14(12):1252-62. PubMed ID: 11743048
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Increased androgen receptor gene copy number is associated with TMPRSS2-ERG rearrangement in prostatic small cell carcinoma.
    Wang L; Williamson SR; Zhang S; Huang J; Montironi R; Davison DD; Wang M; Yao JL; Lopez-Beltran A; Osunkoya AO; MacLennan GT; Baldridge LA; Du X; Cheng L
    Mol Carcinog; 2015 Sep; 54(9):900-7. PubMed ID: 24777847
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunohistochemistry for ERG expression as a surrogate for TMPRSS2-ERG fusion detection in prostatic adenocarcinomas.
    Chaux A; Albadine R; Toubaji A; Hicks J; Meeker A; Platz EA; De Marzo AM; Netto GJ
    Am J Surg Pathol; 2011 Jul; 35(7):1014-20. PubMed ID: 21677539
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Characterization of TMPRSS2-ERG fusion high-grade prostatic intraepithelial neoplasia and potential clinical implications.
    Mosquera JM; Perner S; Genega EM; Sanda M; Hofer MD; Mertz KD; Paris PL; Simko J; Bismar TA; Ayala G; Shah RB; Loda M; Rubin MA
    Clin Cancer Res; 2008 Jun; 14(11):3380-5. PubMed ID: 18519767
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.